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Abstract
Background: European chemicals legislation (registration, evaluation, authorisation and restriction of chemical
substances (REACH)) requires a broad assessment of chemicals with respect to, inter alia, their health-relevant
properties. Due to the extreme number of substances to be assessed and the limited current toxicological
knowledge on their respective properties, REACH implicitly requires a paradigm change: away from knowledge
generated mainly from costly animal experiments towards the use of mechanistic findings. Moreover, effect
mechanisms at the biochemical or cellular level are essential when conclusions shall be drawn about “new”
endpoints and mixtures of xenobiotics. This study (funded by the German Federal Environment Agency) describes
examples of biochemical processes in the mammalian organism and how xenobiotics interfere with them.
Interference with physiological processes expected to lead to adverse health effects is characterised as “toxicity
pathway”. The study describes toxicological endpoints not usually covered in routine animal testing and the
respective toxicity pathways.
Results and conclusions: Screening for chemicals which exert effects via common toxicity pathways and
subsequently conducting targeted short-term tests may generate new information about the toxicity of chemicals
without performing extensive substance-by-substance animal experiments. Information on common toxicity
pathways may also provide input for the assessment of mixture effects. The U.S. Environmental Protection Agency
is working intensely on this concept. It involves the use of enormous amounts of data on relevant biochemical and
cellular processes, which are generated by “high-throughput screening” methods, and then are combined with
substance-specific kinetic data, experimental apical test outcomes and modelling. Current limitations in the
regulatory use of this integrated approach on risk assessment will be outlined.
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Background
This manuscript comprises the theoretical background
and conclusions made in a project initiated and published
by the German Federal Environment Agency (see also
“Acknowledgments”). The literature work was performed
in between February of 2009 and March 2010. Further
details beyond this summary can be taken from the origi-
nal report available at the German Federal Environment
Agency (FKZ 3708 61 205) [1]. Theoretical basis of this
study is that European chemicals legislation requires the
systematic study of marketed chemicals for, inter alia,
properties of relevance to health (REACH: http://echa.
europa.eu/legislation/reach_legislation_en.asp). Animal
studies that describe adverse effects on health (or their
absence) are mainly used for this purpose, although the
underlying mechanism of action does not have to be
known. However, carrying out relevant in vivo studies is
difficult to reconcile with animal welfare concerns and
may be extremely costly. Moreover, their validity is lim-
ited and incomplete in several respects:
• The animal model is not always suited to detect all
xenobiotic-related health effects on humans (in qualita-
tive and quantitative terms).
• Currently, comprehensive tests are generally only
required if a large tonnage is to be placed on the mar-
ket. In the case of small amounts, however, the scope of
testing is minimal although potential toxic effects from
point exposure sources on consumers and workers,
whether directly or indirectly via the environment, are
of substantial interest.
• Real contaminant exposures are often based on expo-
sure to several substances. It seems impossible, however,
to put such exposure scenarios to comprehensive testing
and to describe or even quantify their effects.
Against this background, efforts are increasingly being
made to investigate substances’ mechanisms of action at
the biochemical and cellular levels and to take the
results into account in their toxicological assessment.
The present study:
• Describes toxic effect mechanisms using biochemical
processes influenced by xenobiotics as an example, and
• Subsequently, generates hypotheses of effects that
have, up to now, not been observed in animal studies
and explains how they can be tested
• For both, individual substances and mixtures of
substances.
• It also examines the suitability of already existing
instruments such as (quantitative) structure-activity rela-
tionship ((Q)SAR) to obtain information on xenobiotics’
mechanisms of action and
• Reports on approaches in regulatory toxicology that
aim at linking effect-related testing of xenobiotics with
generating information on their mechanism of action.
Results
Biochemical and cellular events and the impact of
xenobiotics
Metabolic functions, such as the supply of cells with
energy, the catalysis of metabolic transformation by
enzymes, the transport of substances into the extracellu-
lar space or through membranes and communication
based on a feedback control system via signalling chains,
are fundamental processes in an organism. As an intro-
duction, this study gives examples of biochemical and
cellular events that are associated with such metabolic
functions, transport processes, or signal transduction,
and describes, again by way of example, how some
xenobiotics may interfere with the functions mentioned.
In cases where all of the underlying steps of xenobiotic
interference with the organism are known, one would
talk of the substance’s “mechanism of action”, i.e. bind-
ing to a specific receptor which elicits a certain subse-
quent known cascade of events. In cases of a less
detailed knowledge of the substance’s interaction with
the organism, one would refer to “mode of action” as
this indicates only a certain area of biochemical interac-
tion, e.g. it is known that the substance interferes with
DNA repair but without the knowledge of the actual
mechanism. In this manuscript, we aim to address the
mechanism of action of the mentioned xenobiotic
examples.
Energy is supplied through cellular respiration in the
mitochondria in the form of high-energy adenosine tri-
phosphate (ATP). However, there are xenobiotics that
can penetrate the mitochondrial membrane, then trap
protons and transport them away, thereby disturbing
cellular respiration, i.e. uncoupling ATP synthesis from
it, thus leading to energy depletion. Exemplary 2,4-
dinitrophenol, weak organic acids or other acidic phe-
nols are able to induce this biochemical uncoupling
[2].
In the citric acid cycle, which is also important for
energy provision, citrate is converted to isocitrate by the
enzyme aconitase. Fluorocitrate is able to inhibit this
enzyme by forming a complex with the catalytic centre
of the enzyme, thus stopping the citric acid cycle; it may
be metabolised in the body from fluoroacetate, a sub-
stance often used in the past as a rodenticide [3]. This
may induce convulsions and indirectly lead to an acidifi-
cation of the blood [4].
In the human organism, metals that are widespread
due to environmental pollution such as lead behave very
similarly to the physiologically important metal ions of
calcium or zinc. For instance, lead is able to displace
zinc ions in the catalytic centre of the enzyme delta-
aminolaevulinic acid dehydratase and may thereby indir-
ectly induce anaemia due to iron deficiency [5].
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Xenobiotics may also disturb transport processes in
the cell and organism. The process of provision of ATP
to supply energy to cells requires transport of protons
through the mitochondrial membrane. Specific channels
function as routes of transport. Organotin compounds,
for example used as stabilisers in plastics, can obstruct
these channels and thus stop the flow of protons into
the mitochondria [6].
Another transport process necessary for essential bod-
ily functions occurs via a glycoprotein, which transports
xenobiotics from the cells and makes them accessible to
biliary and renal excretion (efflux transporter). These
transporters are mainly expressed in tissues and organs
that form a barrier between “outside” and “inside”. If
such a glycoprotein is confronted with considerable
amounts of xenobiotics, its transport capacity may be
depleted. For instance, artificial and polycyclic musk
compounds, which are present in detergents and cos-
metics as fragrances, have a high affinity to the P-glyco-
protein and may saturate this efflux transporter and
thus contribute to an accumulation of substances in the
cells [7].
Environmental chemicals may also influence those
communication processes in the organism that take
place via signal transduction. Extracellular signal mole-
cules reach a receptor, amplify the signals and after
further signal transductions a cellular reaction results.
Based on the principles of a feedback control system,
feedback will then terminate the reaction. One classical
example of this is how the environment influences the
function of endocrine glands, i.e. thyroidal dysfunction
e.g. due to dietary iodine deficiency. If the thyroid is not
supplied with enough iodine, hormone synthesis does
not regularly take place due to a lack of its basic com-
ponent. The hypothalamic-pituitary feedback system is
disrupted, which may lead to the development of an
iodine deficiency struma [8].
Permanent excitation of nerve cells due to the absence
of negative regulation is another example of the impact
of xenobiotics on one or several control elements of sig-
nal transduction. Neurotransmitters in the brain are sti-
mulated via the opening of specific ion channels to
allow sodium ions to flow into the nerve cell. If
required, this activity is modulated or inhibited by chlor-
ine ions which likewise flow into nerve cells through
specific channels. Lindane (gamma-hexachlorocyclohex-
ane), which formerly was used as a plant protection pro-
duct, prevents the influx of these chlorine ions by
inhibiting the opening of the relevant ion channels. This
results in permanent excitation as mentioned above [9].
It must be stressed, however, that for most xenobiotics
it is not known at all or not known in detail via which
mechanism they act on the organism. In addition, the
following must be borne in mind:
• Substances often act, not via one mechanism alone,
but on different processes at several sites. Since these
processes may be linked with each other, complex inter-
actions may occur.
• As a rule, the finding of a general impact of a sub-
stance (qualitative information) does not allow any con-
clusions to be drawn as to its quantitative effect (Is the
amount absorbed sufficient to induce a disturbance of
the physiological process?).
• Extrapolations to similar substances are possible only
with considerable restrictions because steric changes in
isomers for example may already have major qualitative
and quantitative consequences for an interaction with
biochemical processes.
• Therefore, findings on the mechanism of action
initially represent knowledge-based hypotheses that
must be verified by specific testing and/or may influence
the priority of further investigations. The findings are
generally insufficient to dispense with testing
completely.
Identification of “new” toxic end points
Animal testing as characterised in the Organization for
Economic Cooperation and Development (OECD)
guidelines usually just looks at apical end points and
may readily detect clear-cut adverse effects. Therefore,
the aim of this study was to investigate whether
mechanistic findings on a biochemical or cellular level
would allow the identification of more complex or less
obvious effects of xenobiotics. We describe three exam-
ples of this:
1. Involvement of type-2 alkenes in neurodegenera-
tive processes,
2. Interaction of xenobiotics in delayed hypersensi-
tivity reactions and
3. Mechanistic backgrounds for an increased sensi-
tivity to environmental pollutants in older adults.
Type-2 alkenes and neurodegeneration
Certain type-2 alkenes like propenal can be found in
the brains of patients with Alzheimer’s disease. These
compounds may be formed in the brain endogenously
through ubiquitously occurring reactive oxygen species
(ROS) and may accumulate there over a lifetime. 4-
hydroxy-2-nonenal, for example, is formed in this way.
Also, there is a hypothesis on the mechanism by which
type-2 alkenes might destroy nerve cells. It assumes
that type-2 alkenes mimic the binding of nitrogen
monoxide (NO) to proteins and thereby produce simi-
lar synaptic signal transduction. This has been
confirmed by experimental studies. Since this alkene-
protein binding is irreversible, NO-dependent neuro-
modulation processes are inhibited, resulting in neuron
decay [10,11] (see also Figure 1). A similar effect on
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neurotransmitter activities has been demonstrated for
acrylamide, which is structurally related to propenal
[12]. It must generally be assumed that other alkenes
that are absorbed as xenobiotics may also reach the
brain to produce a similar effect. Substances that can
enzymatically be broken down into such alkenes, such
as certain furan compounds, are also of interest in this
context [13].
On the basis of these mechanistic relationships, it is
recommended that type-2 alkenes and xenobiotics that
metabolise into type-2 alkenes be specifically tested for
potential neurodegenerative effects.
Xenobiotics and delayed hypersensitivity reactions
Glucocorticoids act as immune regulators by inhibiting
the immunoreaction following binding to the glucocorti-
coid (GC) receptor. The following focuses on xenobio-
tics that disturb the function of GC receptors and the
release of cytokine Th1 [14]. Glucocorticoids such as
dexamethasone, an active ingredient of medicinal
products, have an aromatic ring that is necessary to
identify the GC receptor, and they have an agonistic
reagent that “activates” the receptor. If the agonistic
reagent is missing, and the GC receptor is blocked by a
substance (antagonistic binding to the GC receptor), a
cell-mediated, GC-controlled delayed allergy may result.
In the case of structurally similar xenobiotics, it is likely
that they disrupt the flow of signals between the GC
receptors and the hypothalamus. This causes the inflam-
matory reaction of the body to persist despite removal
of the pathogen. The dyestuff tartrazine is assumed to
be able to bind to the GC receptor as tartrazine has a
structure very similar to that of non-steroidal anti-
inflammatory drugs (NSAIDs). However, if such binding
occurred, the receptor would not be activated, since the
agonistic reagent necessary for this is missing. Several
studies have documented hypersensitivity reactions of
the type described here after exposure to tartrazine
[15,16]. We have identified some substances that are
Figure 1 Schematic representation of the molecular mechanism of the neurotoxicity of type-2 alkenes. (A) Sulfhydryl-NO-controlled
processes in neurotransmitter transport: 1. neurotransmitter storage in vesicles; 2. inflow of calcium for vesicle migration to presynaptic
membrane and release of neurotransmitters; 3. uptake of neurotransmitters via post-synaptic membrane; 4. re-entry of excess neurotransmitters
via presynaptic membrane. (B) Disturbance of pumping function by type-2 alkenes. The sulfhydryl-NO bond is physiologically reversible; to
achieve this, pumps and channels are activated, opened and closed as needed (e.g. Ca2+-ion channel, above). Binding of type-2 alkenes is
irreversible, so that control processes can no longer be modulated.
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similar to tartrazine, including four neonicotinoids
which are used as insecticides.
We recommend investigating whether tartazine-like
substances also reach sensitive sites, e.g. pulmonary
epithelial cells, in this form (stability testing) and, if so,
whether they sufficiently accumulate there, have a simi-
lar interaction with the GC receptor and act as aller-
gens. This might be a “new” end point since the regular
chemical testing programme does not include determi-
nation of the immunoglobulin D antibody levels to be
considered here.
Sensitivity to environmental pollutants in aged people
Protein folding takes place in the lumen of the granular
endoplasmic reticulum (ER). If this does not proceed
properly, the accumulation of misfolded proteins may
result in cytotoxic effects, e.g. in the brain [17]. It is
assumed that lead, for example, has an impact on the
endoplasmic reticulum by interfering with potassium
homoeostasis and thus contributes to typical age-related
diseases (such as Huntington’s disease and Alzheimer’s
disease) [18,19]. A similar mechanism is postulated for
various other substances on the basis of gene expression
analyses, e.g. for nonylphenol, di-(2-ethylhexyl)phthalate
and methoxychlor (analysis of the Comparative Toxico-
genomics Database (CTD); http://ctd.mdibl.org/). For an
organism which exhibits low efficiency of various speci-
fic protective mechanisms due to age (formation of cha-
perones in the ER, which are responsible for correct
folding; degradation of misfolded proteins via the ERAD
mechanism; endoplasmic reticulum-associated degrada-
tion) it seems to be plausible that such stress caused by
the abovementioned xenobiotics in the endoplasmic
reticulum would contribute to these typical age-related
diseases. Findings on the mechanism of action involved
will allow this to be verified in a targeted way. There is
also the suspicion of a combined effect in the form of
increased damage to the endoplasmic reticulum through
concurrent exposure to several of these substances.
Combined effects
As indicated, findings on the mechanism of action of an
individual substance also provide indications of com-
bined effects from concurrent exposure to similar sub-
stances, whereby both an intensification of effects and
competitive behaviour may play a role. We pursued this
aspect:
• By analysing the mechanism of the action of sub-
stances via the Ah receptor as well as the consequences
of an exposure to several chemicals exhibiting the same
mechanism of action,
• By discussing the mechanisms whereby different
substances are able to induce cardiovascular effects
together, either on the basis of their similarity or on the
basis of their adverse, but supplementary effects, and
• By evaluating examples from the literature, which (a)
dealt with mechanistic considerations of a combined
effect or in which (b) mixtures of substances were actu-
ally tested and the combined effect was compared with
the effect of the individual substances.
Mixtures and Ah receptor-mediated effects
“Toxicity equivalents” of dioxins and dioxin-like sub-
stances are a well-known example of the application of
biochemical/mechanistic findings in regulation for the
assessment of combined effects [20]. In this example,
interactions between xenobiotics and the intracellular
Ah receptor play a key role (aryl hydrocarbon receptor;
a physiological ligand of the receptor is not known to
date). The Ah receptor is a transcription factor that is
inactively present in the cytoplasm, translocates into
the nucleus after activation by xenobiotics and stimu-
lates the transcription of responsive genes there. These
genes are associated with cell growth and cell differen-
tiation [21,22]. For various mixtures of tetrachlorodi-
benzodioxin, pentachlorodi-benzofuran and
polychlorinated biphenyl 126, toxicity equivalents cor-
relate very well with the effects. However, a more in-
depth analysis also shows that mixtures of substances
that interact with the Ah receptor have effects that are
inconsistent with a simple linear correlation. For
example:
• Metabolites inhibiting the usual Ah receptor-
mediated mechanism can be formed via interaction with
the Ah receptor (probably by inhibition of an enzymatic
degradation of cytochrome or by overexpression of this
cytochrome (e.g. CYP1A1)),
• A mixture may contain closely related polycyclic
aromatic hydrocarbons that act either as receptor ago-
nists (such as benzo(a)pyrene) or as antagonists (such as
fluoranthene), which means that consequences from
opposite effects that cannot exactly be quantified to date
would have to be considered, although the site of action
is the same.
These examples show that the observation of an inter-
action, e.g. with the Ah receptor, is not always sufficient
in itself to draw conclusions about the mechanism of
combined effects with sufficient certainty.
Complex mixtures and cardiovascular diseases
Although cardiovascular diseases are among the most
common lifestyle-based conditions, testing of individual
substances in bioassays does not explicitly cover this
effect. This may mean that too little significance is
ascribed to environmental chemicals in that respect.
However, in epidemiological studies, a close correlation
has been established between exposure to mixtures like
dust, diesel soot, or tobacco smoke and cardiovascular
diseases [23-25]. Nevertheless, understanding of the
effect mechanisms involved is lacking or must be
extended.
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Hypertension is closely related to cardiovascular dis-
eases. Mechanisms that impair the vasodilatation of
blood vessels may play a role in this disease. Redox-
reactive hydrocarbons in diesel engine emissions can
inhibit the activity of the enzyme that synthesises NO,
which may lead to a lowering of the NO level and
reduced vasodilatory capacity [26]. CYP450-catalysed
epoxidation of fatty acid has a role to play in the
endothelial-derived hyperpolarisation factor (EDHF)
[27], which is relevant to vasodilatation. Disturbances by
reactive oxygene species (ROS) and Ah receptor-active
substances interfere with the activity of CYP450
enzymes (e.g. lower CYP induction), impairing the
EDHF and thus the desired vasodilatation. Polycyclic
aromatic hydrocarbons in airborne dust, tobacco smoke,
and diesel soot contain Ah receptor-active substances
and also cause hypertension in this way [28]; in addition,
diesel soot increases ROS production to produce corre-
sponding effects [29].
Reactive oxygen species also cause oxidation of the
low-density lipoprotein (LDL) circulating in the blood,
which is a factor in the development of atherosclerosis
[30-32]. Elevated quantities of oxidised LDL (oxLDL)
result in increased expression of a certain receptor
(LOX-1) through which oxLDL is taken up into the cell,
and this in turn leads to an additional increase of ROS
in the cell [30,33]. This ROS production exceeds the
detoxification capacity of endogenous antioxidants and
induces, e.g. necrosis, apoptosis, or cells with damaged
DNA [34]. Poly(ADP-ribose) polymerase-1 (PARP-1)
cannot cope with excessive DNA damage, resulting, e.g.
from combined action of the substances mentioned, in
base excision repair, and will then induce the above-
mentioned cell death instead of repair [35].
The interactions become so complex that it is very
difficult to draw more exact quantitative conclusions
despite a better understanding of the mechanisms of
action (see Figure 2). The oxidising potential of mixtures
or their impact on NO production is a helpful para-
meter to assess their potential contribution to cardiovas-
cular diseases. Substances inhibiting the interaction
between PARP-1 and DNA are to be regarded as parti-
cularly critical. However, it seems that no quantitative
conclusions about the considered combined effects can
currently be drawn.
Examples of tested combinations of substances having a
common mechanism of action
The widely used pesticides fenarimol, vinclozolin, and
acephate have been assessed as individual substances,
which showed that all three substances are substrates
for enzymes of the cytochrome P450 enzyme family
(CYP) and induce CYP in the same way. As a result,
CYP-dependent enzymes can also be expressed to an
increased or decreased extent. The pesticides mentioned
lead to increased hydroxylation of testosterone in the
(mouse) liver, as indicated by increased testosterone
hydroxylase activity. Tests for CYP induction, NADPH
reductase activity and other CYP-dependent enzyme
activity changes by certain mixtures of the pesticides
showed no clear picture. In any event, the results do not
allow the prediction of an antagonistic, synergistic, or
additive effect of the substances in the mixture [36].
This demonstrates how questionable it may be to draw
conclusions from the testing of individual substances to
the interaction of mixtures and how much uncertainty
may be involved when extrapolating from one mixture
to another.
Ghisari and Bonefeld-Jorgensen [37] investigated the
effects of various plasticisers (phthalates and adipates)
and structurally related substituted phenols which are
used as components of or additives in plastics as well as
phenolic components of herbicides. The study focused
on the combined oestrogenic effect and on thyroid hor-
mone regulation: Simultaneous exposure below the
effect level (no observed adverse effect concentration
(NOAEC)) of the individual compounds did not lead to
receptor activation. However, simultaneous exposure to
the individual effect concentrations (lowest observed
adverse effect concentration (LOAEC)) brought a poten-
tiation of effects, which deviated slightly from additivity.
The study shows that the conclusion that the oestrogen
receptor is always involved in the mechanism of action
does not provide sufficient information for defining the
type of influence that several components have on the
effect. With regard to thyroid hormone regulation, the
effect of the mixture at the NOAECs of the individual
substances was the same as that of the individual sub-
stances. A stimulating effect on proliferation was
observed at the LOAECs, but this effect was smaller
than that of the most effective individual substances.
The effect of the mixture in that regard was subadditive.
In the context of the complex influences on triiodothyr-
onine(T3)-induced cell growth, the study showed how
difficult it is to formulate a generalisable prediction of
the effects of complex mixtures even if mechanistic ele-
ments are included in the analysis.
Structure-activity analysis to identify “new” toxic end
points
The use of structure-activity relationships (SAR) and
quantitative structure-property relationships/quantitative
structure-activity relationships (QSPR/QSAR) is one
possible approach to avoid animal experiments [38]. In
our study, we explored to what extent mechanistic con-
siderations are already integrated in (Q)SAR models
today and whether (Q)SAR models may be applied to
the “new” end points and example substances charac-
terised above.
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Mechanistic considerations in the analysis of (quantitative)
structure-activity relationships
Two different approaches are generally applied to the
analysis of (quantitative) structure-activity relationships:
• Rule-based systems and
• Statistical methods.
With rule-based systems, empirical rules established
and verified by experts are systematised by means of a
computer and applied to predict the presence or
absence of specific properties. An essential basis for
this is the presence or absence of specific functional
groups in a molecule that are known to be responsible
for a specific effect. This means that an idea about the
mechanism of action usually already exists. The range
of experience cannot be extended by means of the
expert system, however, since the prediction is based
on known rules and therefore requires a defined range
of data.
For the statistical approach, it is also desirable to have
an idea of the mechanism of action (see validity criteria
of the OECD for QSAR), but this is not always the case.
It uses different statistical methods to correlate effects
and structural elements of a chemical molecule. Deriv-
ing a mechanism of action is not possible with this, but
would require further expert knowledge. On the other
hand, new hypotheses about molecular properties can
be established by induction, such as bioavailability or
the ability of a substance to inhibit or enhance the func-
tion of a specific protein in the organism ("extension of
the range of knowledge”).
All approaches assume that similar molecules (or at
least similar molecular substructures) generally lead to
Figure 2 Complexity of molecular mechanisms associated with cardiovascular diseases. The figure shows the processes for vasodilatation,
oxLDL and Ah receptor signal pathways and the interaction between bifunctional alkylating agents (BFAs) and DNA and O6-alkylguanine-DNA-
alkyltransferase (AGT).
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similar effects and that a minimum amount of experi-
mental data is necessary to obtain reliable results.
Application to findings on “new” end points
For the above-described examples, “type-2 alkenes and
neurodegeneration” and “potential glucocorticoid
antagonists with allergenic effects”, QSAR models were
used to investigate whether these models can predict
the assumed effect. However, no QSAR models are
available for neurodegeneration and delayed hypersensi-
tivity reactions. The same is true in most cases for the
more broadly defined end points of neurotoxicity and
immunotoxicity, which may be used as approximations.
A possible reason for this is the absence of a sufficient
amount of experimental data of adequate quality and
from the same experimental configuration. This is cur-
rently the decisive obstacle to the establishment of mod-
els to predict the influence of chemicals on biochemical
parameters [39]. Adequate substance-specific experi-
mental tests to verify the postulated effects are currently
not available, nor can the relevance of chemicals for the
effects considered here be examined by means of QSAR
predictions. In the cases discussed here, the mechanisti-
cally based hypothesis cannot be verified by QSAR,
mainly due to a lack of data. Yet, good QSAR models
may also support a mechanistic hypothesis if the avail-
able data so warrants (or require such a hypothesis for
meaningful data interpretation as a basis for the selec-
tion of the experimental data used for modelling). Some
modules are being developed for the prediction of
immunotoxicity and (delayed) hypersensitivity reactions
as well as for “passage of the blood-brain barrier”.
Therefore, at least for these ("substitute”) end points, it
is expected that possibilities of prediction will be avail-
able in the near future. The use of QSAR in regulatory
toxicology would be a major driver for the development
of QSAR models (e.g. as seen in the pharmaceutical
industry during their attempt to optimize active ingredi-
ents of medicinal products).
Mechanistic approaches in regulatory toxicology, status,
research activities and further approaches
Current relevance in regulatory toxicology
Chemical safety requirements under European chemicals
legislation (REACH) are mostly based on effects testing.
The majority of the OECD tests available for this pur-
pose are end point-oriented, and the mechanism is left
as a black box. Mechanism-based tests exist for only a
few end points. The mouse local lymph node assay
(LLNA; OECD TG 429) is one example. The use of
whole batteries of in vitro tests (combinations of differ-
ent tests) also allows the absence of, e.g. genotoxicity to
be claimed for a substance with sufficient certainty,
without animal experiments. Each of the in vitro tests
applied for this purpose also provides indications as to
the mechanism of genotoxicity.
In other fields, for example in the field of phototoxi-
city (e.g. 3T3 NRU test; OECD TG 432), recognised and
standardised in vitro alternatives to animal experiments
are already being combined with knowledge about
mechanisms.
Activities aimed at avoiding animal studies and stan-
dardising corresponding methods with a view to the
testing of chemicals under relevant EU legislation are
collected in a database at the Institute for Health and
Consumer Protection of the Joint Research Centre
http://ecvam.jrc.it. European legislation requires the
search for and application of such alternative, mechan-
ism-based approaches (see REACH). Research is work-
ing to increasingly meet this demand. However, in order
to satisfy the regulatory requirements, it will be neces-
sary to develop combinations of mechanism-based tests
that can be carried out quickly.
Currently, in vitro tests are often carried out for
screening purposes. Yet, the results from these tests are
also being used increasingly for clarifying mechanisms
of action or for gaining a better understanding of them.
In most cases, in vitro tests are not sufficient to replace
animal studies. Most of these tests have not yet been
validated, and their regulatory relevance is therefore not
clear [see reviews 40, 41].
Comparative toxicogenomics database (CTD)
The CTD is a tool to identify genes and their interaction
with a specific chemical [42] and the disease that is
associated with that interaction. It is based on the jour-
nal articles included in the PubMed literature database
and uses data from the NLM database OMIM (Online
Mendelian Inheritance in Man®) with regard to associa-
tions between a gene and disease and from the KEGG
(Kyoto Encyclopedia of Genes and Genomes) system for
information about signal transduction pathways.
The database is updated every month and currently
(as at October 2009) includes about:
• 195,000 chemical-disease associations
• 190,000 chemical-gene interactions
• 670,000 gene-disease associations.
CTD data are prepared with great care and effort,
including the standardisation and (hierarchic) organisa-
tion of the vocabulary used.
The database offers an abundance of search options
and tools, and the search results include many links (up
to the underlying PubMed entry). The CTD generally
offers the possibility to obtain information about poten-
tial diseases mediated by chemicals and is at present
unique in this form. However, the information provided
is often of an indirect nature, and the underlying data
must always be critically reviewed in detail. They can,
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nevertheless, be used as guidance for further searches.
CTD is only one database with toxicogenomic informa-
tion, although it is the most important one for toxicolo-
gical questions.
The concept of the U.S. EPA
In 2007, an expert commission of the U.S. Environmen-
tal Protection Agency (U.S. EPA) and of the U.S.
National Institute of Environmental Health Services at
the National Research Council (NRC) published a fun-
damental report: “Toxicity testing in the 21st century: a
vision and a strategy” [43]. The publication is a central
document in current regulatory toxicology. The consid-
erations of the NRC and EPA are based on an analysis
of the shortcomings in the current procedure of toxico-
logical risk assessment. The experts specifically con-
sulted for this purpose saw the following limitations in
toxicity testing of chemicals as practised to date:
• The uncertainty inherent in using data from ani-
mal studies,
• Extrapolation of a high dose (animal study with a
small number of animals) to a lower dose relevant to
humans,
• Development of ever more end point-related tests,
which will continue to be necessary in future, since
relevant end points have not adequately been
addressed in the present test system making corre-
sponding retesting of substances necessary,
• The ethical issue of animal protection and
• The Aggravation of that problem in view of the
call for more extensive testing of additional toxicolo-
gical end points for further substances (the central
issue in REACH), as well as
• The extremely high costs involved,
• The insufficient possibility of a characterisation of
mixtures, and finally
• The insufficient assignment to risk groups or life
stages.
Against this background, the NRC considers the cur-
rent test strategy to be a dead end and is proposing a
“completely new” concept [also see symposium sum-
mary 44] in the form of a bottom-up approach. In this
concept, data on physicochemical and biochemical para-
meters would be determined and used to establish or
predict the toxicity of a substance in humans. In rare
cases, the prediction would need to be verified via ani-
mal studies, which would then be carried out in a tar-
geted manner. Such a concept requires the generation
of a large number of substance-specific data that provide
information about the interaction of substances with the
organism, e.g. via in vitro systems. State-of-the-art meth-
ods (e.g. genomics, proteomics and metabonomics) are
available for this today.
To predict the properties and toxicity of substances on
the basis of already existing data and computer-based
models, the EPA has created the electronic information
system, Aggregated Computational Toxicology Resource
(ACToR) [45], which is associated with the predictive
EPA programme ToxCast™ [46]. During the first phase
of this programme, a toxicological profile was estab-
lished for more than 300 chemicals whose toxicological
behaviour is known from in vivo tests, and these profiles
were stored in the database as validation set [47]. Toxi-
city was also assessed for these substances by means of
in vitro and in silico methods (the CTD discussed above
is also integrated in ACToR). Based on the substance
activity profiles, an attempt was made to generate a pat-
tern for the prediction of toxicity in in vivo tests. In a
second phase, predictability will be increased, and a
more differentiated selection of chemicals tested. In the
third and most important phase, the knowledge that was
collected in phases one and two will be used to set prio-
rities for the chemicals to be tested [48,49]. Searches in
both ToxCast and ACToR require a harmonised lan-
guage and conventionalised input of the chemical struc-
tures of the substances concerned. The system for this
is supplied via the Distributed Structure-Searchable
Toxicity Database Network project (DSSTox).
The consistent methodological use of recent knowl-
edge in an integrated approach is something radically
new. However, individual elements, e.g. determination of
toxicity via mechanistic studies, use of genomics or inte-
gration of QSAR elements, have been explored for some
time now and, in individual cases, have already been
applied over the last 10 years.
Discussion and conclusions
The study presented here takes up a highly topical issue
of the development of toxicological testing strategies
and their integration in regulatory toxicology. Similar
discussions in the U.S.A. have started and led to initial
provisional results only recently. This issue is being pur-
sued intensely in the U.S.A. by means of the “Toxicity
testing in the 21st century: a vision and a strategy” con-
cept. Yet, the fact that the American authorities under-
line its visionary character also demonstrates that this
approach, which is based on mechanistic toxicity path-
ways, is still at its beginnings. The concept must be
further developed before it can be fully integrated into
regulatory toxicology.
By focusing on new end points and mixtures, the
study deals with one aspect of this paradigm shift in
regulatory toxicology that still has a particularly vision-
ary character. On account of the complexity involved,
uncertainties due to lacking knowledge, and limited
availability of data on “new” end points (such as Alzhei-
mer’s disease, specific immunotoxic mechanisms or
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ageing), it is not yet possible to establish hypotheses
with sufficient reliability and validate them comprehen-
sively. As regards mixtures, the study showed that due
to an abundance of competing and interacting mechan-
istic steps, it is still difficult in that area to identify the
toxicity pathway decisive for the resulting total effect
and to draw (at least semi-)quantitative conclusions.
In our opinion, it is nevertheless essential to continue
the considerations made here and, as regards the effect
of chemicals, to draw more attention to those “new” end
points that have hardly been considered in the past.
Likewise, methods should be developed that provide
qualified answers about the adverse effects of complex,
heterogeneous mixtures of substances. This could lead
to the insight, for example, that the furan compounds
considered here should be investigated in more detail in
that regard.
Even if it can be expected that it will not be possible
to confirm some of the hypotheses put forward on the
similarity of the effects of the substances considered,
examples of this kind are helpful for broadening effects-
based approaches and for more adequately integrating
additional conditions that may need to be taken into
account.
For mixtures containing a relatively small number of
interacting substances, commonly affected end points
and/or commonly affected alterations in gene or protein
expression could be detected by means of the CTD and
alterations postulated in this way could be verified
experimentally for the specific mixture. Effects testing
could thus be concentrated on particularly relevant end
points that can justifiably be assumed to exist.
To promote such a mechanistic approach, all those
performing risk assessments for individual substances
should take fundamental findings on effect mechanisms
(more strongly) into account in the future and docu-
ment them. Although current risk assessment mono-
graphs often contain a passage on “mechanism/mode of
action” for the effect regarded as critical, this does not
usually include information on how the findings were
generated, e.g. by “-omics” analyses, and in what form
they may be stored in, e.g. the CTD. Such considerations
may also be of interest for end points that are regarded
as non-critical in line with the “new” end points
addressed above.
In the case of effect end points for which the available
data are still insufficient to allow a final assessment to
be made, considerations based on crystallographic meth-
ods in conjunction with information on toxicity path-
ways may be taken into account in their assessment,
using a read-across method, even if current (Q)SAR
models do not address the end point considered.
Some suitable high-throughput screening methods are
already available for end point-related research. They
should be used to identify individual priority substances
for more specific testing. The base data should be input
into existing tools to provide an improved database for
other users.
Extensive knowledge of toxicity pathways will present a
particular problem for the methodology applied today to
assess the risks of and determine limit values for chemical
substances and mixtures. The “no observed effect level”
and the “lowest observed effect concentration” are core
elements of such assessments. In view of biochemical or
cellular changes and disturbances far below an adverse
effect observable “from outside”, it seems obvious that the
taxonomy of the adversity concept should be updated.
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